$MSA (MSA Safety Incorporated)

$MSA {{ '2016-09-19T22:13:28+0000' | timeago}} • Announcement

Global safety equipment manufacturer $MSA announced it has acquired Senscient, Inc., a leader in laser-based gas detection technology used in industrial, oil and gas production and petrochemical processing applications. The terms of the deal were not disclosed.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$AVY {{ '2017-07-27T13:45:12+0000' | timeago}} • Announcement

$AVY has declared a quarterly cash dividend of $0.45 per share on its common stock. The dividend is payable on September 20, 2017, to shareholders of record as on September 6, 2017.

$CYH {{ '2017-07-27T12:33:35+0000' | timeago}} • Announcement

Hospital operator $CYH said it expects 2Q17 operating revenue to be about $4.1Bil, lower than $4.6Bil recorded last year. The company sees a net loss of $137MM or $1.22 per share for the quarter, compared to the $1.431Bil loss recorded in 2Q16. Adjusted EBITDA is estimated at $435MM, compared to $563MM a year earlier.

$PII {{ '2017-07-27T12:05:16+0000' | timeago}} • Announcement

$PII has declared a regular quarterly cash dividend of $0.58 per share on its common stock. The dividend is payable on September 15, 2017, to shareholders of record as on September 1, 2017.

$ALXN {{ '2017-07-27T11:31:03+0000' | timeago}} • Announcement

$ALXN's sale of its flagship drug Soliris was $814MM in 2Q17, compared to $701MM in the prior-year period, representing a 16% increase. Soliris volume increased 18% YoY. Soliris is primarily used to treat a rare disorder that destroys red blood cells.

$ALXN {{ '2017-07-27T11:20:47+0000' | timeago}} • Announcement

$ALXN raised its 2017 forecast for both GAAP and non-GAAP revenue to $3.45-3.525Bil, vs the prior guidance of $3.40-3.50Bil. Non-GAAP EPS projection for this period was also raised to $5.40-5.55, compared to the prior guidance of $5.10-5.30. Meanwhile, the company now sees GAAP EPS in the range of $2.82-3.12.

$ALXN {{ '2017-07-27T11:10:27+0000' | timeago}} • Announcement

Global biopharmaceutical company $ALXN reported 21% jump in revenue in 2Q17 to $912MM. The revenue reflected a benefit of about $35MM due to favorable timing of orders compared to its prior forecast. Net income rose to $165MM, or $0.73 per share, from $120MM, or $0.53 per share, a year ago. On an adjusted basis, $ALXN earned $1.56, up 38% YoY.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$EW {{ '2017-07-26T20:43:20+0000' | timeago}} • Announcement

For 3Q17, $EW projects underlying sales, adjusting for the impact of Germany stocking sales consumption, to be between $810-850MM, and adjusted earnings per share of $0.80 to $0.90.

$EW {{ '2017-07-26T20:42:56+0000' | timeago}} • Announcement

For FY17, $EW's full year sales estimate is now at the high end of its previous $3.2-3.4Bil guidance. Edwards Lifesciences Corp is also raising its estimate for FY17 adjusted earnings per share to $3.65-3.85, from $3.43-3.55.

$EW {{ '2017-07-26T20:40:21+0000' | timeago}} • Announcement

With strong demand for TAVR therapy resulted in total sales growth of 15% on an underlying basis, $EW's 2Q17 sales soared 11% to $841.8MM. Net income for the quarter jumped 47% to $186.1MM or $0.86 per diluted share. Adjusted earnings per share grew 42.1% to $1.08 while underlying sales rose 15% to about $864MM.

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$UTX {{ '2017-07-26T15:22:39+0000' | timeago}} • Webcast

$UTX still expects 2018 is going to be the peak for negative engine margin at Pratt & Whitney. $UTX has still coming down on 87% learning curve on the engine. Pratt is working through all things such as engineering changes to drive some cost out of the engine, and overhead support costs for supply chain that will play into product cost next year.

$UTX {{ '2017-07-26T15:10:11+0000' | timeago}} • Webcast

For UTC Aerospace Systems, $UTX expects commercial OEs to be up in the 2H17 a little bit. But overall for the full year, the company expects flattish commercial OE. On the other hand, $UTX does expect the commercial aftermarket business to be up mid-single digit as opposed to the low single digit the company expected before.

$UTX {{ '2017-07-26T15:01:00+0000' | timeago}} • Webcast

Based on 1H17 results and anticipated increases in negative engine margin in 2H17, $UTX still sees Pratt & Whitney full-year operating profit being down $150-200MM, but likely closer to the $200MM end of the range. With solid 1H results at Aerospace Systems, $UTX still sees operating profit to be up $50-100MM for 2017 and likely toward high end.

$UTX {{ '2017-07-26T14:57:29+0000' | timeago}} • Webcast

$UTX expects improvement in 2H17, driven by strength in equipment orders, productivity initiatives, and lower FX headwind. $UTX still sees Climate, Controls & Security (CCS) operating profit to grow by $100-150MM at actual FX in 2017, but likely closer to the low end. $UTX now sees that CCS will see low to mid-single-digit organic sales growth.

$UTX {{ '2017-07-26T14:48:26+0000' | timeago}} • Webcast

$UTX still expects to spend about $3.5Bil on share repurchases this year, completing its plan to return $22Bil to shareowners between 2015 and 2017. On the M&A front, those closed at UTC Climate, Controls & Security and Otis last year are contributing to growth story this year, and $UTX continues to have a placeholder at $1-2Bil for M&A this year.

$UTX {{ '2017-07-26T14:44:52+0000' | timeago}} • Webcast

At UTC Climate, Controls & Security, where $UTX continued to invest in new products and sales resources, organic growth was 5% in 2Q17, with organic growth in the North American residential business up double digits. Equipment orders grew 11%, and that follows strong new equipment orders growth of 7% in 1Q17.

Recent Transcripts

EW (Edwards Lifesciences Corp.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AVY (Avery Dennison Corporation)
Tuesday, July 25 2017 - 4:00pm
HUBB (Hubbell Inc.)
Tuesday, July 25 2017 - 2:00pm
UTX (United Technologies Corporation)
Tuesday, July 25 2017 - 12:30pm
PHG (Koninklijke Philips N.V)
Monday, July 24 2017 - 8:00am
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
PII (Polaris Industries Inc.)
Thursday, July 20 2017 - 2:00pm
DOV (Dover Corporation)
Thursday, July 20 2017 - 2:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
IVC (Invacare Corporation)
Tuesday, May 9 2017 - 12:30pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
MSI (Motorola Solutions, Inc.)
Thursday, May 4 2017 - 9:00pm
SPXC (SPX Corporation)
Thursday, May 4 2017 - 8:45pm
KAMN (Kaman Corporation)
Thursday, May 4 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
CYH (Community Health Systems, Inc.)
Tuesday, May 2 2017 - 4:00pm
MTRN (Materion Corporation)
Friday, April 28 2017 - 1:00pm

AlphaGraphics you may like